- Home
- IRWD
as 05-09-2025 4:00pm EST
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 150.9M | IPO Year: | 2010 |
| Target Price: | $4.94 | AVG Volume (30 days): | 4.0M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.59 - $8.23 | Next Earning Date: | 05-07-2025 |
| Revenue: | $317,676,000 | Revenue Growth: | -23.18% |
| Revenue Growth (this year): | -21.86% | Revenue Growth (next year): | -6.36% |
Stock Insider Trading Activity of Ironwood Pharmaceuticals Inc. (IRWD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| John Minardo | IRWD | Chief Legal Officer | Feb 10 '25 | Sell | $1.76 | 38,938 | $68,530.88 | 408,132 | |
| MCCOURT Thomas A | IRWD | Chief Executive Officer | Feb 10 '25 | Sell | $1.76 | 139,064 | $244,752.64 | 1,160,634 | |
| Shetzline Michael | IRWD | SVP, CMO, Head-Res&Drug | Feb 10 '25 | Sell | $1.76 | 41,269 | $72,633.44 | 554,007 | |
| Silver Ronald | IRWD | Principal Accounting Officer | Feb 10 '25 | Sell | $1.76 | 12,048 | $21,204.48 | 279,655 | |
| Martini Gregory S. | IRWD | Chief Financial Officer | Feb 10 '25 | Sell | $1.76 | 12,052 | $21,211.52 | 183,810 |
Latest Ironwood Pharmaceuticals Inc. News
IRWD Breaking Stock News: Dive into IRWD Ticker-Specific Updates for Smart Investing
Zacks
a day ago
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
Zacks
3 days ago
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
Associated Press Finance
3 days ago
Ironwood: Q1 Earnings Snapshot
Business Wire
3 days ago
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
Zacks
3 days ago
Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks
8 days ago
Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for
Business Wire
9 days ago
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
Business Wire
15 days ago
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
Compare IRWD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IRWD Ironwood Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.